BIODESIX INC
BDSX · XNASCIK 1439725fmd_0F7R3MJXJ0WZDN5DP2R3D2ERKZServices · Services-Medical LaboratoriesTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 31 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 25 | 46 | 55 | 38 | 49 | 71 | 88 |
| Provision for credit losses | – | – | – | – | 0 | 1 | 0 |
| Research and development | 10 | 11 | 13 | 13 | 10 | 10 | 12 |
| Selling, general and administrative | 31 | 35 | 51 | 61 | 67 | 80 | 88 |
| Total operating expenses | 51 | 68 | 95 | 89 | 90 | 106 | 116 |
| Operating income | (27) | (23) | (41) | (51) | (41) | (34) | (28) |
| Interest expense | 3 | 8 | 5 | 8 | 10 | 8 | 8 |
| Other non-operating income (expense) | (4) | (8) | (2) | (15) | (11) | (8) | (7) |
| Income tax expense | – | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (31) | (65) | (43) | (65) | (52) | (43) | (35) |